CLINICAL TRIALS PROFILE FOR RESERPINE

All Clinical Trials for RESERPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000499 ↗	Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Completed	National Institute on Aging (NIA)	Phase 2	1980-09-01	The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000499 ↗	Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1980-09-01	The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000514 ↗	Systolic Hypertension in the Elderly Program (SHEP)	Completed	National Institute on Aging (NIA)	Phase 3	1984-06-01	The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00000514 ↗	Systolic Hypertension in the Elderly Program (SHEP)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1984-06-01	The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	Centers for Disease Control and Prevention	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	National Eye Institute (NEI)	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.

Clinical Trial Conditions for RESERPINE

Condition Name

Condition Name for RESERPINE
Intervention	Trials
Hypertension	5
Cardiovascular Diseases	3
Heart Diseases	2
Cocaine-Related Disorders	2

Condition MeSH

Condition MeSH for RESERPINE
Intervention	Trials
Hypertension	6
Cardiovascular Diseases	3
Heart Diseases	2
Disease	2

Clinical Trial Locations for RESERPINE

Trials by Country

Trials by Country for RESERPINE
Location	Trials
United States	22
Canada	2
China	2
France	1
Puerto Rico	1

Trials by US State

Trials by US State for RESERPINE
Location	Trials
Ohio	4
Florida	2
California	2
Tennessee	2
Alabama	1

Clinical Trial Progress for RESERPINE

Clinical Trial Phase

Clinical Trial Phase for RESERPINE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
Phase 2	4

Clinical Trial Status

Clinical Trial Status for RESERPINE
Clinical Trial Phase	Trials
Completed	10
Unknown status	2
TERMINATED	1

Clinical Trial Sponsors for RESERPINE

Sponsor Name

Sponsor Name for RESERPINE
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	3
National Institute on Aging (NIA)	3
National Heart, Lung, and Blood Institute (NHLBI)	3

Sponsor Type

Sponsor Type for RESERPINE
Sponsor	Trials
NIH	11
Other	9
U.S. Fed	3

Reserpine Clinical Trials Update and Market Analysis Projection (2025-2035)

Last updated: April 27, 2026

What is resperpine (reserpine) and what do the clinical trial records show?

Reserpine is a classic antihypertensive and antipsychotic-adjunct alkaloid used primarily for hypertension and, historically, psychiatric indications. Current industry activity is dominated by legacy repositioning, formulary/derivative products, and ongoing observational or small interventional studies rather than late-stage, brand-defining Phase 3 programs.

Trial-type signal: what appears in public registries

Across major registries (notably ClinicalTrials.gov and regional equivalents), resperpine activity is sparse and typically clusters into one of these buckets:

• Bioequivalence and formulation studies (often in tablets, oral solutions, or re-formulated salts)
• Small clinical pharmacology studies (dose-ranging or safety/tolerability in specific populations)
• Observational or retrospective studies (drug utilization, outcomes in real-world cohorts)

There is no consistent evidence of a contemporary, large global Phase 3 pipeline that would indicate a near-term, label-expanding asset renewal led by a modern development program.

Where do the trials stand now? (2023-2026 registry trend)

Public resperpine trial records are dominated by “completed,” “terminated,” or “unknown status” entries, with fewer new starts in the last few years relative to the broader antihypertensive pipeline. When new records appear, they usually relate to:

• Generic/bioequivalent product support
• Local regulatory submissions
• Post-marketing observational work

What this implies for development risk and timelines

For decision-makers, the practical signal is that resperpine’s near-term clinical value creation is less about novel clinical efficacy and more about:

• Product lifecycle management
• Regulatory maintenance
• Formulation optimization

That profile generally shifts value capture toward manufacturing, supply chain, and regulatory speed rather than R&D breakthroughs.

---

How is the resperpine market positioned today?

Reserpine competes within the antihypertensive universe that is now dominated by:

• RAS inhibitors
• ARBs
• CCBs
• Diuretics
• Newer fixed-dose combinations

Reserpine pricing power is constrained by:

• Low differentiation
• Generic availability
• Patient and prescriber preference moving toward better-tolerated, guideline-aligned therapies
• Safety and tolerability considerations that limit broad first-line use

Market structure characteristics

Reserpine exposure tends to be concentrated in:

• Established generics markets
• Institutional procurement (where cost sensitivity is high)
• Niche formularies where older antihypertensive options remain used

---

What does the competitive landscape look like?

Competition is not driven by patent exclusivity for a modern, brand-led program. The competitive set is primarily:

• Generic manufacturers
• Regional brands with historical distribution
• Substitutable antihypertensives

Key competitive dynamics:

• Downward pricing pressure from multi-source generic supply
• Formulation and dosing advantages as the main differentiators
• Regulatory and quality system readiness as a gating factor for expansion

---

What is the likely commercial trajectory for resperpine (2025-2035)?

Given the absence of a visible, late-stage label-expansion development engine, a defensible projection is that resperpine behaves like a legacy/generic antihypertensive: stable demand with periodic volatility based on supply and formulary inclusion.

Base-case market projection framework (directional)

Because resperpine is widely generic and lacks a modern proprietary pipeline signature, the main drivers over 2025-2035 are:

• Population growth and hypertension prevalence
• Switching to newer first-line therapies
• Reimbursement and procurement practices
• Supply continuity and plant capacity

Base-case projection (qualitative)

• Total addressable demand for antihypertensives grows with disease burden
• Reserpine share is pressured by guideline-aligned therapies
• Revenue grows slower than the class, unless a region-specific reversion occurs (supply disruptions or procurement shifts)

Range logic (qualitative)

• Upside: increased access through low-cost procurement in additional markets and sustained stable supply
• Downside: further formulary erosion, substitution to better-tolerated options, and supply interruptions that cause stock-outs

---

What about patent and exclusivity constraints?

Reserpine is a historic compound with earlier patent history long expired in essentially all major jurisdictions. Current value creation therefore does not rely on molecule-level exclusivity, but on:

• Local formulation protections (if any exist in specific geographies)
• Regulatory exclusivity for specific product formats (rare for fully generic compounds)
• Manufacturing process and quality differentiation
• Branding and distribution execution

This shifts valuation away from “clinical breakthrough optionality” toward execution and compliance.

---

Clinical trial update: key items to track for resperpine

For investors and R&D operators, the meaningful monitors are not efficacy signals but registry and regulatory artifacts that indicate commercial readiness:

1. New bioequivalence starts
   • Usually linked to product launches and dossier refreshes.
2. Change-of-manufacturer or process validation filings
   • These can affect supply reliability more than trial outcomes.
3. Safety surveillance or observational cohorts
   • Useful for risk-management positioning, especially where older agents face tighter scrutiny.
4. Regional approvals and formulary updates
   • Often the fastest indicator of market momentum.

---

Market strategy implications (2025-2035)

If you are a generic manufacturer

• Optimize for dossier throughput and tight release timelines.
• Keep focus on stable supply, quality systems, and cost competitiveness.
• Treat trials as regulatory enablers rather than clinical differentiation.

If you are an investor

• Underwrite revenue primarily on market access and distribution, not pipeline novelty.
• Model downside with share loss driven by guideline substitution.
• Treat any new interventional trial activity as product-iteration evidence unless it shows large-scale efficacy endpoints (which is not the observed pattern for resperpine).

---

Key Takeaways

• Reserpine clinical activity is dominated by legacy-style and formulation/bioequivalence or small safety/observational studies, not a modern Phase 3 label-expansion pipeline.
• The market is a generic, competition-heavy antihypertensive space with pricing pressure and limited differentiation.
• A 2025-2035 outlook is best framed as stable demand with share erosion risk, driven by substitution to newer guideline therapies and procurement patterns.
• Value creation is likely to come from regulatory execution, supply continuity, and regional access, not clinical breakthrough economics.

---

FAQs

1. Is resperpine still being studied in modern clinical trials?
   Yes, but activity is generally limited and skewed toward formulation, bioequivalence, pharmacology, or observational work rather than late-stage efficacy trials.

2. What drives resperpine demand most in 2025-2035?
   Hypertension prevalence, low-cost procurement, and continued formulary inclusion in certain regions, offset by substitution toward newer agents.

3. Will resperpine likely gain a new label indication based on current trial patterns?
   The current trial signal does not indicate a strong probability of major label expansion driven by large-scale modern Phase 3 evidence.

4. How does patent status affect resperpine’s commercial outlook?
   Molecule-level patents are largely expired, so commercial outcomes depend on generic execution and any product-specific regulatory protections.

5. What should companies prioritize for competitiveness?
   Regulatory readiness, bioequivalence performance, manufacturing capacity stability, and localized access strategy.

---

References (APA)

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov
[2] World Health Organization. (n.d.). WHO Model List of Essential Medicines. https://www.who.int/medicines/publications/essentialmedicines/en/
[3] FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] European Medicines Agency. (n.d.). European public assessment reports and medicine information. https://www.ema.europa.eu/